Can Photobiomodulation Help Prevent Oral Mucositis During Cancer Treatment? A Clinical Evidence Review

For many patients receiving chemotherapy or radiotherapy, the greatest challenge isn't always the cancer itself. It is the inability to eat, drink, or speak without pain. Oral mucositis affects most patients undergoing intensive treatment for head and neck cancers, and severe cases can interrupt the very therapies intended to control the disease. Preventing that interruption has made supportive care a growing focus in oncology, bringing photobiomodulation into clinical practice guidelines for selected patients.

This review examines what the current evidence shows, drawing primarily on a 2025 narrative review published in Nowotwory. Journal of Oncology, along with the clinical trials and guidelines it synthesizes.

Oral mucositis is inflammation and ulceration of the mucous membrane lining the mouth, caused by the cytotoxic effects of chemotherapy or radiotherapy on rapidly dividing epithelial cells. It typically begins as redness and thinning of the mucosa before progressing to open ulceration as treatment continues, most often affecting the inner cheeks, the floor of the mouth, the soft palate, and the edges of the tongue.

The condition is widespread among cancer patients undergoing intensive treatment. It affects an estimated 85 to 100 percent of head and neck cancer patients receiving radiotherapy, and 70 to 100 percent of patients undergoing high-dose chemotherapy or total body irradiation ahead of stem cell transplantation. Onset is usually within the first weeks of treatment, with severity typically peaking around five weeks into radiotherapy and six weeks into combined chemoradiotherapy.

Clinically, oral mucositis is significant beyond patient discomfort. Pain reduces oral intake, increasing the risk of dehydration and malnutrition, a risk that is elevated in children and older adults. Ulceration also creates a route for infection, which becomes more dangerous when combined with the neutropenia that chemotherapy frequently causes.

Oral mucositis develops through five overlapping biological stages, beginning at the cellular level well before any ulcer becomes visible.

Initiation. Radiation or chemotherapy damages the DNA of basal epithelial cells, triggering early cell death and releasing reactive oxygen species within the tissue.

Primary damage response. These reactive oxygen species activate transcription factors, most notably NF-kB, which begins upregulating genes involved in inflammation.

Signal amplification. NF-kB activation increases production of pro-inflammatory cytokines, including interleukin-1 beta, interleukin-6, and TNF-alpha. Multiple biological pathways interact at this stage, compounding tissue injury.

Ulceration. The mucosa breaks down into a pseudomembrane or open ulcer, exposing nerve endings and producing pain. Bacterial penetration of the underlying tissue can now occur, triggering additional inflammatory response.

Healing. Resolution generally occurs without intervention, though its pace depends on the patient's immune status, overall health, and the supportive therapies used during treatment.

Photobiomodulation is a non-invasive therapy that uses red light in the 600 to 700 nanometer range and near-infrared light in the 700 to 950 nanometer range, delivered by lasers or LEDs, to influence cellular activity without generating significant heat. Researchers propose that its primary site of action is the mitochondrion, specifically an enzyme called cytochrome c oxidase, which plays a central role in cellular energy production.

The proposed mechanism functions as follows. Light absorption by cytochrome c oxidase is thought to support electron transport in the respiratory chain, increasing ATP production. This process also appears to generate a controlled release of reactive oxygen species, which influences gene transcription and NF-kB activity, prompting the release of growth factors involved in tissue repair.

A second proposed pathway involves nitric oxide. In stressed or oxygen-deprived cells, nitric oxide can bind to cytochrome c oxidase and block the respiratory chain, reducing ATP output and worsening oxidative stress. Photobiomodulation is thought to displace nitric oxide from this binding site, restoring energy production while allowing free nitric oxide to support the body's stress response and cell survival signaling.

These mechanisms are grounded in laboratory and mitochondrial research rather than direct clinical measurement. The review is explicit that this represents a proposed model rather than a fully established biological pathway.

Clinical evidence indicates that photobiomodulation is most effective when initiated before mucositis develops, rather than after symptoms appear. In a study of multiple myeloma patients undergoing stem cell transplant conditioning, those who began treatment on the first day of conditioning developed markedly less severe mucositis than those treated only after onset. At seven days post-treatment, the preventive group had a median severity score of 1, compared to 3 in the reactive group, with corresponding pain scores of 1.1 versus 6.7 out of 10.

Photobiomodulation also appears to reduce treatment-related weight loss. In a study of head and neck cancer patients receiving radiotherapy, those treated with photobiomodulation lost an average of 2.72 kilograms, compared to 5.71 kilograms in patients who did not receive it, with a corresponding difference in body mass index reduction.

Treatment frequency affects outcomes, though an optimal protocol has not been firmly established. One trial found that daily sessions produced substantially better outcomes than sessions every other day, with severe mucositis developing in 25 percent of the daily group compared to 75 percent of the alternating-day group. A separate trial found that three sessions per week produced results statistically indistinguishable from daily treatment, indicating that protocol design still requires refinement.

Photobiomodulation has also demonstrated favorable cost-effectiveness. One trial calculated an incremental cost of approximately 857 dollars per patient, with a cost-effectiveness ratio of roughly 2,867 dollars to prevent one case of severe mucositis, concluding that the therapy was cost-effective largely by reducing treatment interruptions.

Taken together, this evidence points to a measurable clinical benefit, particularly with early and consistent application. It remains, however, a body of individual trials with varying protocols rather than a single unified dataset.

Current guidelines support the use of photobiomodulation as a preventive measure in two defined patient populations, not as a general therapy for all cancer patients. The Mucositis Study Group of the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology, known by the shorthand MASCC/ISOO, recommends intraoral photobiomodulation for head and neck cancer patients undergoing radiochemotherapy or high-dose chemotherapy, and for patients receiving high-dose conditioning chemotherapy before stem cell transplantation, with or without total body irradiation.

Two aspects of this recommendation carry clinical significance. First, the guidance addresses prevention specifically, consistent with the trial data on treatment timing. Second, it applies to defined populations rather than cancer patients broadly, reflecting where the strongest supporting evidence currently exists.

Several aspects of photobiomodulation protocol design remain under active investigation.

Intraoral versus extraoral delivery. Intraoral photobiomodulation delivers light directly to specific points inside the mouth and requires greater patient cooperation. Extraoral delivery is administered from outside the mouth and is easier to apply, though it must penetrate more tissue to reach the target area. One trial found the two approaches produced similar clinical outcomes, with extraoral sessions averaging under two minutes compared to nearly six minutes for intraoral delivery.

Optimal laser power. A comparison of 1-watt and 2-watt protocols in stem cell transplant patients found no significant difference in mucositis severity between the two settings, suggesting a workable range of power levels rather than a single fixed value.

Optimal treatment frequency. Findings on daily versus less frequent dosing have not fully converged, and the staffing burden of daily sessions is itself a practical constraint for oncology centers to weigh.

Emerging delivery methods. Ongoing research is evaluating newer device designs and combination approaches, including photobiomodulation paired with photodynamic therapy using natural photosensitizers such as curcumin.

Available clinical evidence has not shown that photobiomodulation, used according to studied protocols, negatively affects cancer survival outcomes, though long-term data remain limited and tumor safety continues to be actively monitored. This is the question that warrants the most careful answer, since it concerns cancer treatment outcomes directly rather than comfort alone.

The underlying concern is biologically plausible: light therapy could, in theory, stimulate residual cancer cells alongside healthy tissue. Researchers have not dismissed this possibility. In a retrospective study of patients with locally advanced oral squamous cell carcinoma who received photobiomodulation for mucositis prevention, overall survival and disease-free survival rates were consistent with outcomes reported elsewhere in the literature for comparable patients. A broader systematic review of 27 articles examining photobiomodulation across multiple cancer treatment toxicities found no evidence of tumor safety issues.

At the same time, the literature is candid that the mechanism by which light could theoretically influence cell proliferation is not fully resolved, and long-term outcome data remain limited. This is why guidelines recommend photobiomodulation within specific, studied contexts rather than as a universal supportive therapy, and why tumor safety remains an area of ongoing research rather than a settled question.

Photobiomodulation shows its clearest evidence-based benefit as a preventive intervention, initiated before mucositis develops, in the two patient populations current guidelines already define: head and neck cancer patients undergoing radiochemotherapy, and patients undergoing high-dose conditioning before stem cell transplantation. Within these groups, the evidence supports reduced severity, less pain, better nutritional status, and fewer treatment interruptions.

Protocol parameters, including power, frequency, and delivery method, still allow room for clinical judgment rather than a single fixed formula, consistent with how supportive oncology often functions in practice, where individualized care tends to outperform a uniform protocol.

For patients and families, photobiomodulation is a therapy worth discussing with an oncology care team, particularly ahead of high-dose chemotherapy or radiotherapy where mucositis risk is greatest. For clinicians less familiar with the modality, the guideline-defined use cases and the evidence on preventive timing offer a reasonable starting point for further review.

This article is based on a 2025 narrative review published in Nowotwory. Journal of Oncology (Bakuła et al., DOI: 10.5603/njo.104765), along with the clinical trials, systematic reviews, and guidelines cited within it, including MASCC/ISOO clinical practice guidelines. It is intended for informational purposes and does not constitute medical advice. Patients should consult their oncology care team before starting any supportive therapy during cancer treatment.